Skip to main content

Table 1 Baseline characteristics of patients according to trajectory-based clustering

From: Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis

 

Total

(N = 688)

Group 1

(N = 319)

Group 2

(N = 36)

Group 3

(N = 290)

Group 4

(N = 43)

p

Age, year

52.9 (12.2)

52.0 (12.3)

53.6 (13.2)

53.6 (12.1)

54.4 (11.1)

0.324

Male sex, n (%)

97 (14.1)

46 (14.4)

7 (19.4)

35 (12.1)

9 (20.9)

0.318

Body mass index, kg/m2

22.4 (3.4)

22.2 (2.9)

22.5 (2.7)

22.7 (3.8)

22.4 (4.2)

0.723

Symptom duration, year

7.2 (7.1)

7.1 (7.2)

8.3 (8.4)

7.2 (6.9)

7.6 (7.5)

0.925

Smoking, n (%)

 Current smoker

38 (5.5)

11 (3.4)

1 (2.8)

20 (6.9)

6 (14.0)

0.018

 Ex-smoker

55 (8.0)

28 (8.8)

3 (8.3)

19 (6.6)

5 (11.6)

0.601

 Never smoker

595 (86.5)

280 (87.8)

32 (88.9)

251 (86.6)

32 (74.4)

0.112

Prednisolone dose*, mg

5.1 (3.7)

4.9 (3.7)

5.9 (6.4)

5.1 (3.2)

5.2 (3.6)

0.570

Methotrexate dose, mg

10.5 (5.6)

10.6 (5.3)

11.3 (4.9)

10.3 (5.8)

9.3 (6.7)

0.885

Hemoglobin, g/dL

12.0 (1.4)

12.2 (1.3)

12.0 (1.1)

11.9 (1.4)

11.6 (1.5)

0.014

ALT, IU/L

19.2 (12.5)

19.2 (11.6)

20.1 (12.4)

19.0 (12.3)

20.0 (18.5)

0.393

AST, IU/L

21.2 (9.8)

20.9 (7.1)

21.6 (6.9)

21.3 (9.0)

23.5 (24.1)

0.463

BUN, mg/dL

14.2 (4.5)

14.5 (4.5)

14.0 (4.3)

13.7 (4.2)

15.6 (5.9)

0.118

eGFR, mL/min/1.732m2

101.2 (26.7)

101.2 (26.9)

104.1 (26.4)

101.2 (26.9)

97.9 (25.1)

0.702

Cholesterol, mg/dL

174.3 (27.7)

171.4 (27.0)

171.1 (22.0)

178.6 (28.7)

169.0 (26.5)

0.054

ESR, mm/h

49.2 (25.4)

43.0 (22.9)

54.6 (31.7)

54.5 (25.2)

55.6 (28.8)

 < 0.001

CRP, mg/dL

2.2 (2.8)

2.1 (2.4)

2.7 (2.8)

2.4 (3.2)

2.0 (2.1)

0.376

ANA positivity, n (%)

247 (35.9)

116 (36.4)

13 (36.1)

104 (35.9)

14 (32.6)

0.971

RF positivity, n (%)

595 (86.5)

275 (86.2)

32 (88.9)

255 (87.9)

33 (76.7)

0.240

ACPA positivity, n (%)

515 (74.9)

238 (74.6)

27 (75.0)

220 (75.9)

30 (69.8)

0.859

Initial DAS28

5.68 (0.95)

5.4 (0.9)

5.5 (1.2)

5.9 (0.9)

6.1 (1.0)

 < 0.001

  1. Data are mean (standard deviation) unless noted otherwise
  2. ACPA, anti-cyclic citrullinated peptide antibody; ALT, alanine aminotransferase; ANA, anti-nuclear antibody; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C-reactive protein; DAS28, disease activity score with 28-joint assessment; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor
  3. *Glucocorticoid dose (e.g., prednisolone, methylprednisolone, deflazacort, and dexamethasone) was converted to prednisolone doses
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us